INFLIXIMAB DE-ESCALATION IN PATIENTS WITH CROHN'S DISEASE IN CLINICAL REMISSION IS SAFE AND WELL TOLERATED

被引：0
|
作者：
Allegretti, Jessica R.
McClure, Emma L.
Marcus, Jenna
Norton, Beth Ann
Hamilton, Matthew
Winter, Rachel
De Silva, Punyanganie
Friedman, Sonia
Korzenik, Joshua R.
机构：
来源：
GASTROENTEROLOGY | 2020年 / 158卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1874
引用
收藏
页码：S461 / S461
页数：1
相关论文
共 50 条
  • [41] Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients
    Baert, Filip
    Glorieus, Ellen
    Reenaers, Catherine
    D'Haens, Geert
    Peeters, Harald
    Franchimont, Dennis
    Dewit, Olivier
    Caenepeel, Philippe
    Louis, Edouard
    Van Assche, Gert
    JOURNAL OF CROHNS & COLITIS, 2013, 7 (02): : 154 - 160
  • [42] Serology panel for prediction relapse after discontinuation of infliximab in patients with Crohn's disease achieving clinical remission
    Papamichail, K.
    Claes, K.
    de Bruyn, M.
    Hauenstein, S.
    Princen, F.
    Singh, S.
    Van Assche, G. A.
    Rutgeerts, P. J.
    Vermeire, S.
    Ferrante, M.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S295 - S296
  • [43] Serology Panel for Prediction of Relapse After Discontinuation of Infliximab in Patients With Crohn's Disease Achieving Clinical Remission
    Papamichael, Konstantinos
    Claes, Karolien
    de Bruyn, Magali
    Princen, Fred
    Singh, Sharat
    Van Assche, Gert A.
    Rutgeerts, Paul J.
    Vermeire, Severine
    Ferrante, Marc
    Hauenstein, Scott
    GASTROENTEROLOGY, 2015, 148 (04) : S865 - S865
  • [44] The effects of vitamin D3 supplementation on clinical remission in patients with Crohn's disease treated with infliximab
    徐缘
    China Medical Abstracts (Internal Medicine), 2022, (02) : 107 - 108
  • [45] Persistent inflammatory markers and deregulated immune response in clinical remission Crohn's disease patients treated with infliximab
    Murillo, Duarte-Silva
    Rogerio, Parra
    Marley, Feitosa
    Omar, Feres
    Joaquim, Rocha Jose
    Cristina, Cardoso
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S10 - S11
  • [46] Maximum Tolerated Dose Estimation with Dose De-Escalation Design in a Phase I Clinical Trials
    Jang, Eunah
    Kim, Dongjae
    KOREAN JOURNAL OF APPLIED STATISTICS, 2014, 27 (07) : 1115 - 1123
  • [47] Do infliximab trough levels differ between adult and paediatric patients with Crohn's disease in clinical remission?
    Cavazza, A.
    Mavroeidi, N.
    Steel, A.
    Greathead, L.
    Kelleher, W.
    Wahed, M.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S340 - S340
  • [48] Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation
    Cathy Lu
    Alistair Waugh
    Robert J Bailey
    Raeleen Cherry
    Levinus A Dieleman
    Leah Gramlich
    Kata Matic
    Mario Millan
    Karen I Kroeker
    Daniel Sadowski
    Christopher W Teshima
    Dennis Todoruk
    Clarence Wong
    Karen Wong
    Richard N Fedorak
    World Journal of Gastroenterology, 2012, (36) : 5058 - 5064
  • [49] CLINICAL AND LABORATORY VARIABLES THAT PREDICT CLINICAL AND ENDOSCOPIC REMISSION IN CHILDREN WITH CROHN'S DISEASE TREATED WITH INFLIXIMAB
    D'Arcangelo, G.
    Oliva, S.
    Tarani, F.
    Viola, F.
    Cucchiara, S.
    Aloi, M.
    DIGESTIVE AND LIVER DISEASE, 2016, 48 : E269 - E270
  • [50] Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation
    Lu, Cathy
    Waugh, Alistair
    Bailey, Robert
    Cherry, Raeleen
    Dieleman, Levinus A.
    Gramlich, Leah
    Matic, Kata
    Millan, Mario
    Kroeker, Karen I.
    Sadowski, Daniel
    Teshima, Christopher W.
    Todoruk, Dennis
    Wong, Clarence
    Wong, Karen
    Fedorak, Richard N.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (36) : 5058 - 5064
12345